IPSC
Century Therapeutics, Inc. (IPSC) SWOT Analysis Analysis (2026)
No material changes this month.
Overall Score
Strengths
Strong liquidity with a current ratio of 8.28x and cash ratio of 3.29x.
Low leverage with debt-to-equity of 0.15x and debt-to-assets of 0.12x.
Shares trade at a low price-to-book of 1.79x and price-to-fair-value of 1.79x.
Weaknesses
Profitability remains deeply negative, with ROE of -52.8%, ROA of -38.3%, and ROIC of -43.7%.
Margins are still at 0% across gross, operating, EBITDA, and net profit lines.
Free cash flow remains negative, with free cash flow yield of -50.5% and operating cash flow yield of -48.0%.
Opportunities
A very high current ratio provides flexibility to fund operations and development without near-term liquidity pressure.
Low valuation multiples could re-rate if the company demonstrates a path to profitability.
Positive working capital of $109.7M offers room to support execution.
Threats
Persistent losses and negative cash generation increase financing and dilution risk if execution does not improve.
The company’s negative earnings yield and free cash flow yield indicate the market is still pricing in substantial uncertainty.
Weak solvency ratio of -1.83x underscores ongoing balance-sheet and operating risk.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Century Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.